|
|
immatics begins Imprint phase III trial to treat renal cell carcinoma - pharmabiz.com |
pharmabiz.com
We look forward to confirming the positive overall survival data seen in the phase II study as advanced renal cell cancer still has a very high unmet medical need.” Paul Higham, CEO of immatics added: “An overall survival benefit combined with a stable
|
|
|
Research and Markets: The Nephrology and Urology Devices Market Outlook in ... - Gamut News (press release) |
Gamut News (press release)
The Nephrology and Urology Devices Market Outlook in Taiwan to 2017 – Incontinence Devices, Renal Dialysis Equipment and Others report provides key market data on the Taiwanese Nephrology and Urology Devices market. The report provides value (USD
|
|
Nocturnal Dialysis th a Cairns first - Media Newswire (press release) |
Media Newswire (press release)
A 49-year-old Cairns renal dialysis patient has been the first Cairns patient to trial Nocturnal Dialysis th an at-home process which allows dialysis treatment throughout the night while a patient sleeps. (Media-Newswire.com) - A 49-year-old Cairns
|
|
New Kidney Filtration System Could Simplify Dialysis - UCSF Today |
UCSF Today
UCSF researchers have designed a model filtration system that could offer a new approach to treating patients suffering from end-stage renal disease, potentially removing the need for a clinic-based dialysis process altogether.
|
|
Renal kallikrein excretion and epigenetics in human acute kidney injury ... - 7thSpace Interactive (press release) |
7thSpace Interactive (press release)
Renal kallikrein (KLK1) synthesis and urinary excretion are reportedly diminished during AKI (acute kidney injury) in animal models, and provision of kallikrein abrogates renal injury in this setting, but data in human AKI is limited.
|
|
|
|
|
<< Start < Prev 841 842 843 844 845 846 847 848 849 850 Next > End >>
|
|
Page 849 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
